Registered number: 06981121
Charity number: 1132271
ASSOCIATION FOR GLYCOGEN STORAGE DISEASE (UK) LIMITED
(A company limited by guarantee)
UNAUDITED
TRUSTEES. REPORT AND FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025

ASSOCIATION FOR GLYCOGEN STORAGE DISEASE (UK) LIMITED
(A company limited by guarantee)
CONTENTS
Page
Reference and administrative details of the company, its Trustees and advisers
Trustees, report
Independent examinerfs report
10
Statement of financial activities
11
Balance sheet
12
Notes to the financial statements
13-30

ASSOCIATION FOR GLYCOGEN STORAGE DISEASE (UK) LIMITED
(A company limited by guarantee)
REFERENCE AND ADMINISTRATIVE DETAILS OF THE COMPANY, ITS TRUSTEES AND ADVISERS
FOR THE YEAR ENDED 31 MARCH 2025
Trustees
Nicholas Jones (resigned 18 January 2026)
Ailsa Arthur
Sarah Chikhani
Rachel Thomas
Dr Florence Osborne. Chair
Dr Charlotte Dawson
Kempton Rees
Karolina Stepien (appointed 18 January 2026)
Company registered number
06981121
Charlty registered number
1132271
Registered office
Black Country House, Rounds Green Road. Oldbury, West Midlands. B69 2DG
Independent examlner
Crowe U.K. LLP, Black Country House, Rounds Green Road, Oldbury, West Midlands. B69 2DG
Page 1

ASSOCIATION FOR GLYCOGEN STORAGE DISEASE (UK) LIMITED
(A company limited by guarantee)
TRUSTEES. REPORT
FOR THE YEAR ENDED 31 MARCH 2025
The Tnjstees present their annual report together with the financial statements of the company for the year 1
April 2024 to 31 March 2025. The Annual report serves the purposes of both a Trustees, report and a directors,
report under company law. The Trustees confinn that the Annual report and financial statements of the
charitable company comply with the current statutory requirements, the requirements of the charitable companls
governing document and the provisions of the Statement of Recommended Practice (SORP) applicable to
charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and
Republic of Ireland (FRS102} (effective 1 January 2019).
Since the company qualifies as small under section 382 of the Companies Act 2006, the Strategic report
required of medium and large companies under the Companies Act 2006 (Strategic Report and Directors,
Report) Regulations 2013 has been omitted.
Objectives and activities
a. Policies and objectives
The objects of the Association for Glycogen Storage Disease (UK) as recorded in its Memorandum of
Association, is "The relief of sickness, particularly of persons suffering from any form of Glycogen Storage
Disease" The Association works to protect and promote the best interests of persons affected by GSD.
Public Benefit
The Trustees confirm that they have complied with the duty in section 17 of the Charities Act 2011 to have due
regard to public benefit guidance published by the Commission in determining the activities undertaken by the
Charity.
The Charity Commission in its 'Charities and Public Benefit" Guidance states that there are key principles to
be met in order to show that an organisation's aims are for the public benefit: firstly, there must be an identifiable
benefit and secondly, that benefit must be to the public or a section of the public. The Trustees are satisfied that
the aims and objectives of the charity. and the activities reported on below to achieve those aims, meet these
principles.
b. Strategies for achieving objectives
The Association acts as a vehicle of communication on GSD related matters by publishing and distributing
relevant material. It contributes to the advancement of treatments and cures through sponsorship of research,
studies and trials. It acts as a focus for educational, scientific and charitable activities related to GSD. The
Association liaises with other GSD Associations around the world. Please see Review of activities section for
details of our current strategy.
c. Activities undertaken to achieve objectives
The main activities are the support of patients and families. the organising of conferences and workshops to
promote understanding of the disease- the publication of a newsletter., the provision of information about
Glycogen Storage Disease through publications and a web site- and the provision of grants to research bodies
and individuals. These activities support the objects by assisting patients- by encouraging and supporting
research into the disease and by educating the medical profession and concemed members of the general
public about the disease.
Page 2

ASSOCIATION FOR GLYCOGEN STORAGE DISEASE (UK) LIMITED
(A company limited by guarantee)
TRUSTEES. REPORT (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
Objectives and activities (continued)
d. Grant-making policies
The Association receives applications for grants to support research projects in relation to Glycogen Storage
Disease. Applications for grants are considered by the Board of Trustees and by members of the Association's
Medical Advisory Board. Whenever possible the Association co-sponsor together with other charities or
foundations. The Association also occasionally makes small grants to individual applicants for personal
expenses associated with their treatment, care and well-being.
Achievements and perforniance
a. Review of activities
During the 2024-25 financial year we continued to work towards the goals of our current strategic plan. These
are drawn from priorities identified by community members and comprise:
Theme: Support across the community-
Goal: Everyone affected will be connected to an active and supportive GSD community.
Theme= Help with living well.
Goal: People with any GSD will be offered the information and activities they need to live well with the condition.
Theme" Better treatments and service access.
Goal: The community will experience improved management. treatment and Servi￿ access.
Theme: Strong and effective organisation.
Goal: AGSD-UK will grow sustainably, with robust governance. to increase our impact.
Support across the community
Over the course of the year the intensive advocacy provided by our care and benefits advisors enabled
community members to access much needed services such as home adaptations and equipment grants,
education and health care packages, transport, enhanced social care and a range of welfare benefits. Individuals
and families also received valued support with issues like dealing with diagnosis. parenting and employment
rights.Their feedback included:
'AGSD UK truly is a breath of fresh air for people facing the challenges of rare conditions. Your charity
provides more than just advice. you offer a lifeline of empathy, understanding, and non-judgmental support
to those who need it most..
.1 would like to express my heartfelt gratitude to AGSD UK. I have Pompe disease, and at times, it can make
you feel isolated. Coping with the constant changes to your health and mobility. as well as the day-to-day
challenges, can be incredibly tough. AGSD UK has been an unwavering source of support for me."
"[AGSD-UK advisors] have been instrumentsl in guiding me Ihrough the complexities of benefit programs,
including DLA and carer's allowan￿. and have also provided invaluable assistance in assessing my overall
benefit entitlements. Their support extended beyond paperwork. as they even helped me access food
vouchers during times of real hardship."
Page 3

ASSOCIATION FOR GLYCOGEN STORAGE DISEASE (UK) LIMITED
(A company limited by guarantee)
TRUSTEES. REPORT (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
Achievements and perforniance (continued)
Our local get-togethers connecting people with others affected also received a very positive response from those
attending=
'We had an amazing time and thoroughly enjoyed ourselves. It was such a valuable experience to meet
other families facing similar health challenges. which made us feel much less isolated."
Living wth such a rare condition can be tough, especially when people don't always understand what we go
through, so connecting wth others who do was incredibly comforting."
.it was great to connect with other parents of children with GSD and share our experiences, challenges
and daily worries."
Help with living well
Two McArdle's walking courses for under 21s and for adults took place in Wales during July and August 2024
and, as usual, were greatly appreciated by those taking part:
"Just wanted to thank you again for organising the walking course and encouraging me to come on it. I had a
great time and feel like I learnt a lot.-
'These weekendslweeks are life-changing and life-affirming. From the bottom of my heart, thank you all for
an amazing week."
"The twns got to be with other teens. young people and older McArdleites. They got to climb mountains they
(and we) would never have attempted and do physical things that were bold and audacious."
.1 enjoyed the amazing walks that we went on and the cooking. I really liked the activities we did after the
walks, like bracelet making, playing games and paddling in the river!"
Our monthly Living well socials continue to be extremely well received and a thriving WhatsApp group has been
developed alongside the meetings to facilitate mutual support=
"Wonderful place to be. Love how positive it is. Thank you... for this safe space"
Our regular Glisten magazine packed with information about living with GSDS was widely distributed and further
information sheets produced. Website views for the financial year totalled 38,020.
Our Main Event for the community staged during the 2024-5 financial year again received outstanding feedback.
The evaluation forms completed showed that:
1000/0 said the event enabled them to connect wth others with similar experiences
100°/o said the event gave them the chance to gain tips about living with GSDS
100°/o said the event allowed them to become better informed about research and developments in the field
of GSDS
Page 4

ASSOCIATION FOR GLYCOGEN STORAGE DISEASE (UK) LIMITED
(A company limited by guarantee)
TRUSTEES. REPORT (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
Achievements and perforniance (continued)
100 % said the event provided the opportunity to get information about support and services that are
available
1000/0 said they had fun and enjoyed themselves
The following is just a small selection of the comments received=
'It was superb. Team was great-very helpful. Would like to attend again..
'Good mix of scientific updates. patent support and fun activities."
'Loved the music therapy on Sunday a.m.°
'The whole AGSD-UK team are wonderful-l Ihoroughly enjoyed the meeting."
'We were very impressed with the organisation and the agenda."
'It was a very valuable experience coming to this event with my family as not only did we meet people who
are dealing with the same thing as us but also with professionals who mirror the work they do with our
centre."
'Heartfelt thanks for an incredibly well-organised and impaciful conference...The programme ilself was so
well curated, delivering both depth and relevance that kept us all engaged throughout the weekend...
'Your hard work, attention to detail and dedication made the event run smoothly and successfully. The
sessions were insightful. We truly appreciated it."
'Thank you so much for looking after us. Your care and attention meant a lot. We're truly grateful for
everything you do to keep us comfortable and supported. Thank you."
'This was our first time at the conference. Everyone was really helpful and supportive. Thank you so much..
"Excellent weekend -informative and fun. Thank you."
Better treatments and service access
Throughout the year we continued to support and promote multiple opporlunities for people affected by GSDS to
shape and take part in research and trials to enable the development of better treatments. We also worked with
industry, health professionals and other charity partners to influence service quality.
Work began on the two Loughborough University PhD research programmes relating to diel, exercise and
mental health and digital biomarkers in hepatic GSDS that we are joint-funding with the generous support of the
Mosawi Foundation.
We took part in two further intemational online meetings organised by the Adult Polyglucosan Body Disease
Research Foundation, focused on bringing the APBD and GSD IV communilies togelher to develop a joint action
and communications plan. AGSD-UK was also represented at an Aspire biosciences speed-daling event. this
time with a view to exploring potential partnerships for new trealments for hepatic GSDS.
Page 5

ASSOCIATION FOR GLYCOGEN STORAGE DISEASE (UK) LIMITED
(A company limited by guarantee)
TRUSTEES. REPORT (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
Achievements and perforniance (continued)
Strong and effective organisation
We continued to benchmark the organisation against established voluntary sector standards, strengthening our
processes and policies to ensure these are robust and in line with best practice. This included reviewing ways to
ensure our board remains fully inclusive and open to new members to bring a range of skills, ideas and
perspectives to our governance and cause. We remain extremely grateful to all those who contribute their time,
energy and expertise to help enable AGSD-UK to respond to the needs of those affected by this challenging
condition.
Financial review
a. Going concern
The trustees have reasonable expectation that the company has adequate resources to continue in operational
existence for the foreseeable future. They continue to believe the going concern basis of accounting is
appropriate in preparing the annual financial statements.
b. Reserves policy
The Association holds some funds that are restricted in expenditure in support of particular GSD Types and
other projects {see note 17). The general reserves are used to support the on going activities of the Association.
The unrestricted general reserve now stands at £35.987 which is a decrease from the previous year {£43,596).
The trustees, future focus will be on increasing income while tightly managing costs. The total restricted funds is
now £53,836 (2024: £84.486).
In line with most small charities AGSD UK aims to spend most of the funds raised during any given financial year
for the benefit of its members and the public and not to build up a large general reserve. The trustees have
agreed to adopt a reserve policy that seeks to carry forward an unrestricted general reserve figure that is no
greater than 250/0 of total in year expenditure.
The funds freely available for use by the charity at the year end at the discretion of the Trustees, amount to the
unrestricted reserves less the unrestricted tangible fixed assets of £594. Our free reserves at 31 March 2025 are
therefore £35,393 (2024.. £42,798).
c. Investment policy and perfomiance
The Association holds its cash reserves in bank deposit accounts thus eliminating investment risk and
minimising any other risk to the reserves. No long term deposits are made as it is anticipated that the reserves
will continue to be called upon to support a high level of activity.
Page 6

ASSOCIATION FOR GLYCOGEN STORAGE DISEASE (UK) LIMITED
(A company limited by guarantee)
TRUSTEES. REPORT (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
Structure, governance and management
a. Constitution
The company is registered as a charitable company limited by guarantee and was set up under a Memorandum
of Association. The company is constituted under a Memorandum of Association dated 0510812009 and is a
registered charity number 1132271. The principal object of the company is to provide "The relief of sickness,
particularly of persons suffering from any form of Glycogen Storage Disease..
b. Methods of appointment or election of Trustees
The management of the company is the responsibility of the Trustees who are elected andlor co opted under the
terms of the Articles of Association. Any full member of the Association may be nominated to stand for election
to the Board of Trustees. The Trustees have the power to Co-opt new Trustees who are then required to stand
for election at the next AGM.
. Organisational structure and decision-making policies
The Association is a membership based association, with full membership being open to anyone affected by
Glycogen Storage Disease and the close family of such persons. The members elect the Board of Trustees. The
Board of Trustees elects its own officers. The Board of Trustees are responsible for ensuring that the charity
complies with all relevant regulations and files its annual report and accounts with the Charity Commission and
Companies House.
The Board of Trustees delivers the strategy through the Chief Executive and any other staff plus a range of
volunteers.
The Board appoint a volunteer Co-ordinator for each of the GSD t￿es, wherever possible. The defined role is
wide ranging and is not necessarily entirely relevant or practical for each GSD Type, where the numbers affected
and their needs vary enormously. The C￿OrdInatorS meet as a group three times a year for peer support and
development in their role.
d. Pay policy for key management personnel
The company currently has one part-time permanent member of staff - the Chief Executive, with four part-time
freelance team members.
The remuneration for key management posts was benchmarked at or below market rate prior to appointment
and is reviewed by Trustees annually.
Page 7

ASSOCIATION FOR GLYCOGEN STORAGE DISEASE (UK) LIMITED
(A company limited by guarantee)
TRUSTEES. REPORT (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
Structure, governance and management (continued)
e. Financial risk management
The Twstees have assessed the major risks to which the company is exposed, in particular those related to the
operations and finances of the company. and are satisfied that systems and procedures are in place to mitigate
exposure to the major risks.
f. Risk Management
The Trustees have assessed the major risks to which the company is exposed. The current major risks to the
charity are primarily in the areas of operation and finan￿ as follows=
Income generation
Cost control
Banking control
l.T. stability and security
Adoption of and adherence to policies and procedures
Loss of key personnel
The Trustees are satisfied that systems. procedures and plans are in place to mitigate exposure to major risks.
Plans for future periods
The period April 2025-26 is the last of our current strategy and we remain focused on delivering our stated goals.
This involves further expansion of our support offer and facilitation of peer support, with a wider range of groups
to meet the needs of under-served sections of the community. including children and young people.
We will take forward updating of our website, ensuring this contains the current evidence-based information
people need to help them live well and is attractive. engaging and easy to navigate.
Our ongoing research support will ensure studies and developments in treatment and management are shaped
by the needs of the community.
We will also complete our work to benchmark the organisation against best practice standards for the sector, as
part of our quality improvement cycle.
In addition, we will take forward a community listening exercise to inform the key goals for our next three year
strategy.
To deliver our plans we will continue to support fundraising efforts within the community, while seeking the help
of grant making trusts aligned with our goals and working closely with our valued industry partners.
We would like to express our appreciation to all those individuals and organisations who contribute to our work
and our special thanks go to., Amicus, Beam. Community Fund, D.0￿Y Carte Charitable Trust, Mosawi
Foundation, Sanofi, Ultragenyx and Vitaflo for their commitment to improving lrfe for people affected by GSD.
Page 8

ASSOCIATION FOR GLYCOGEN STORAGE DISEASE (UK) LIMITED
(A company limited by guarantee)
TRUSTEES. REPORT (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
Statement of Trustees, responsibilities
The Trustees (who are also the directors of the company for the purposes of company law) are responsible for
preparing the Trustees, report and the financial statements in accordance with applicable law and United
Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practi￿).
Company law requires the Trustees to prepare financial statements for each financial . Under company law, the
Trustees must not approve the financial statements unless they are satisfied that they give a true and fair view of
the state of affairs of the company and of its incoming resources and application of resources, including its
income and expenditure, for that period. In preparing these financial statements. the Trustees are required to:
select suitable accounting policies and then apply them consistently.
observe the methods and principles of the Charities SORP (FRS 102).,
make judgments and accounting estimates that are reasonable and prudent;
state whether applicable UK Accounting Standards {FRS 102) have been followed, subject to any material
departures disclosed and explained in the financial statements.,
prepare the financial slatements on the going concern basis unless it is inappropriate to presume that the
company will continue in business.
The Trustees are responsible for keeping adequate accounting records that are sufficient to show and explain
the companls transactions and disclose with reasonable accuracy at any time the financial position of the
company and enable them to ensure that the financial statements comply with the Companies Act 2006. They
are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the
prevention and detection of fraud and other l￿egUlarl11es.
Approved by order of the members of the board of Trustees on
2910112026
*okeMce Oiboklle
and signed on their behalf by..
Flor.qnF.o.Q?P.orn¢,'Jon 2.2.2.Q?fr.IA".ie"49.&MTI
Dr Florence Osborne
Chair
Page 9

ASSOCIATION FOR GLYCOGEN STORAGE DISEASE (UK) LIMITED
(A company limited by guarantee)
INDEPENDENT EXAMINER'S REPORT
FOR THE YEAR ENDED 31 MARCH 2025
Independent Examinerfs Report to the Trustees of Association for Glycogen Storage Disease
(UK) Limited ('the company.)
I report to the charity Trustees on my examination of the accounts of the company for the year ended 31 March
2025.
Responsibilities and Basis of Report
As the Trustees of the company (and its directors for the purposes of company law) you are responsible for the
preparation of the accounts in accordance with the requirements of the Companies Act 2006 {'the 2006 Act,).
Having satisfied myself that the accounts of the company are not required to be audited under Part 16 of the
2006 Act and are eligible for independent examination, I report in respect of my examination of the companys
accounts carried out under section 145 of the Charities Act 2011 ('the 2011 Act.). In carrying out my examination
I have followed the Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.
Independent Examinerfs Statement
I have completed my examination. I confimi that no matters have come to my attention in connection with the
examination giving me cause to believe:
accounting records were not kept in respect of the company as required by section 386 of the 2006 Act;
or
the accounts do not accord witt) those records; or
the accounts do not comply with the accounting requirements of section 396 of the 2006 Act other than
any requirement that the accounts give a 'true and fair, view which is not a matter considered as part of
an independent examination. or
the accounts have not been prepared in accordance with the methods and principles of the Statemenl of
Recommended practi￿ for accounting and reporting by charities [applicable to charities preparing their
accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of
Ireland (FRS 102)].
I have no concerns and have come across no other matters in connection with the examination to which
attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.
This report is made solely to the companvs Trustees, as a body, in accordance with Part 4 of the Charities
(Accounts and Reports) Regulations 2008. My work has been undertaken so that I might state to the companls
Trustees those matters l am required to state to them in an Independent examiner's report and for no other
purpose. To the fullest extent permitted by law. I do not ac￿pt or assume responsibility to anyone other than the
company and the companls Trustees as a body, for my work or for this report.
Signed:
Helen Blundell
Dated: 29 January 2026
LLB FCA FCIE DChA
Crowe U.K. LLP
Chartered Accountants
Black Country House
Rounds Green Road
Oldbury
West Midlands
B69 2DG
Page 10

ASSOCIATION FOR GLYCOGEN STORAGE DISEASE (UK) LIMITED
(A company limited by guarantee)
STATEMENT OF FINANCIAL ACTIVITIES (INCORPORATING INCOME AND EXPENDITURE ACCOUNT)
FOR THE YEAR ENDED 31 MARCH 2025
Restricted Unrestricted
funds
funds
2025
2025
Total
funds
2025
Total
funds
2024
Note
Income from:
Donations and legacies
Charitable activities
89,850
60,009
830
149,859
830
277,395
875
Other trading activities
Investments
5.986
16,042
1,235
22,028
1,235
21,738
1,120
1,149
Other income
Total income
95,836
78,116
173,952
242,277
Expenditure on:
Charitsble activities
145.124
67,087
212,211
197,548
Total expenditure
145,124
67,087
212,211
197,548
Net (expenditure)lincome
Transfers between funds
(49,288)
18.638
11,029
(18,638)
(38,259)
44, 729
18
Net movement in funds
(30,650)
(7,609)
(38,259)
44, 729
Reconciliation of funds:
Total funds brought forward
84.486
43,596
128,082
83,353
Total funds carried fO￿ard
53,836
35,987
89,823
128,082
The Statement of Financial Activities includes all gains and losses recognised in the year.
The notes on pages 13 to 30 form part of these financial statements.
Page 11

ASSOCIATION FOR GLYCOGEN STORAGE DISEASE (UK) LIMITED
(A company limited by guarantee)
REGISTERED NUMBER: 06981121
BALANCE SHEET
AS AT 31 MARCH 2025
2025
2024
Note
Fixed assets
Tangible assets
15
594
798
594
798
Current assets
Debtors
Cash at bank and in hand
16
6,149
93,253
3,478
130,666
99,402
134, 144
Current liabilities
Creditors: amounts falling due within one
year
{10,173)
(6,860)
17
Total net assets
89,823
128,082
Charity funds
Restricted funds
18
53,836
35,987
84,486
43,596
Unrestricted funds
18
Total funds
89,823
128,082
The company was entilled to exemption from audit under section 477 of the Companies Act 2006.
The members have not required the company to obtain an audit for the year in question in accordance with
section 476 of Companies Act 2006.
The Trustees acknowledge their responsibilities for complying with the requirements of the Act with respect to
accounting records and preparation of financial statements.
The financial statements have been prepared in accordance with the provisions applicable to entities subject to
the small companies regime.
The financial statements were approved and authorised for issue by the Tnjstees on
2910112026
and signed on their behalf by..
tIpiRnM.Q5kornta4p.L4.L44kLU"A¥;4￿.Q￿vl
Dr Florence Osborne
Chair
The notes on pages 13 to 30 form parl of these financial statements.
Page 12

ASSOCIATION FOR GLYCOGEN STORAGE DISEASE (UK) LIMITED
(A company limited by guarantee)
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025
General information
1.1 Company Status
The Association for Glycogen Storage Disease (UK) Limited is a company limited by guarantee in
England, whose registered office is Black Country House, Rounds Green Road, Oldbury, West
Midlands, B29 2DG. The companls registered number is 06981121. In the event of the company
being wound up. the liability in respect of the guarantee is limited to £10 per member of the
company.
Accounting policies
2.1 Basis of preparation of financial statements
The financial statements have been prepared in accordance with the Charities SORP {FRS 102)
Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities
preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK
and Republic of Ireland (FRS 102) (effective 1 January 2019), the Financial Reporting Standard
applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006.
Association for Glycogen Storage Disease (UK) Limited is a private company limited by guarantee
and meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially
recognised at historical cost or transaction value unless otherwise stated in the relevant accounting
policy.
2.2 Going concern
The trustees have a reasonable expectation that the company has adequate resources to continue in
operational existence for the foreseeable future. They continue to believe the going concern basis of
accounting appropriate in preparing the annual financial statements.
2.3 Income
All income is recognised once the company has entitlement to the income, it is probable that the
income will be received and the amount of income receivable can be measured reliably.
Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is
recognised at the time of the donation.
Income tax recoverable in relation to investment income is recognised at the time the investment
income is receivable.
2.4 Expenditure
Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit
to a third party. it is probable that a transfer of economic benefits will be required in settlement and
the amount of the obligation can be measured reliably. Expenditure is classified by activity. The costs
of each activity are made up of the total of direct costs and shared costs, induding support costs
involved in undertaking each activity. Direct costs attributable to a single activity are allocated directly
to that activity. Shared costs which contribute to more than one activity and support costs which are
not attributable to a single activity are apportioned between those activities on a basis consistent with
the use of resources. Central staff costs are allocated on the basis of time spent, and depreciation
charges allocated on the portion of the asset's use.
Page 13

ASSOCIATION FOR GLYCOGEN STORAGE DISEASE (UK) LIMITED
(A company limited by guarantee)
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025
Accounting policies (continued)
2.4 Expenditure (continued)
Expenditure on charitable activities is incurred on direcdy undertaking the activities which further the
companys objectives, as well as any associated support costs.
Grants payable are charged in the year when the offer is made except in those cases where the offer
is conditional. such grants being recognised as expenditure when the conditions attaching are
fulfilled. Grants offered subject to conditions which have not been met at the year end are noted as a
commitment, but not accrued as expenditure.
Support costs are those costs incurred directly in support of expenditure on the objects of the
company. Governance costs are those incurred in connection with administration of the company and
compliance with constitutional and statutory requirements.
Costs of generating funds are costs incurred in attracting voluntary income. and those incurred in
trading activities that raise funds.
Charitable activities and Governance costs are costs incurred in the companls educational
operations, including support costs and costs relating to the governance of the company apportioned
to charitable activities.
2.5 Cash flow
The company has taken advantage of the exemption in Financial Reporting Standard No.1 from the
requirement to produce a cash flow statement on the grounds that it is a small charitable company.
2.6 Intangible assets and amortisation
Intangible assets costing £500 or more are capitalised and recognised when future economic
benefits are probable and the cost or value of the asset can be measured reliably.
Intangible assets are initially recognised at cost. After recognition, under the revaluation model,
intangible assets shall be carried at a revalued amount, being their fair value at the date of
revaluation less any subsequent accumulated amortisation and subsequent impairment losses
provided that the fair value can be determined by reference to an active market.
Revaluations are made with sufficient regularity to ensure that the carrying amount does not differ
materially from that which would be determined using fair value at the end of the reporting period.
Amortisation is provided on intangible assets at rates calculated to write off the cost of each asset on
a straight-line basis over its expected useful life.
Amortisation is provided on the following basis:
Website development
20 0/0 straight line
Page 14

ASSOCIATION FOR GLYCOGEN STORAGE DISEASE (UK) LIMITED
(A company limited by guarantee)
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025
Accounting policies (continued)
2.7 Tangible fixed assets and depreciation
A review for impairment of a fixed asset is carried out if events or changes in circumstances indicate
that the carrying value of any fixed asset may not be recoverable. Shortfalls between the carrying
value of fixed assets and their recoverable amounts are recognised as impairments. Impairment
losses are recognised in the Statement of Financial Activities incorporating income and expenditure
account.
Tangible fixed assets are initially recognised at cost net of accumulated depreciation and any
accumulated impairment losses. Al costs incurred to bring a tangible fixed asset into its intended
working condition should be included in the measurement of cost.
Depreciation is charged so as to allocate the cost of tangible fixed assets less their residual value
over their estimated useful lives. on a reducing balance basis.
Depreciation is provided on the following basis:
Office equipment
250k reducing balan
2.8 Financial instruments
Debtors
Short term debtors are measured at transaction price. less any impairment.
Creditors
Short term trade creditors are measured at transaction pri￿.
Cash
Cash is represented by cash in hand and deposits with financial institutions repayable without penalty
on notice of not more than 24 hours.
There are no complex financial instruments.
2.9 Pensions
The pension costs charges in the financial statements comprise contributions payable by the Charity
during the year for a defined contribution personal pension plan for staff. The Charity contributes 3 %
of eligible pay for those employees enrolled in the plan.
2.10 Fund accounting
General funds are unrestricted funds which are available for use at the discretion of the Trustees in
furtherance of the general objectives of the company and which have not been designated for other
purposes.
Restricted funds are funds which are to be used in accordance with specific restrictions imposed by
donors or which have been raised by the company for particular purposes. The costs of raising and
administering such funds are charged against the specific fund. The aim and use of each restricted
fund is set out in the notes to the financial statements.
Page 15

ASSOCIATION FOR GLYCOGEN STORAGE DISEASE (UK) LIMITED
(A company limited by guarantee)
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025
Accounting policies (continued)
2.11 Role of Volunteers
The charity relies on the efforts of its volunteers. The value of these volunteers is not incorporated
within the accounts.
Critical accounting estimates and areas of judgment
Estimates and judgments are continually evaluated and are based on historical experience and other
factors, including expectations of future events that are believed to be reasonable under the
circumstances.
Critical accounting estimates and assumptions:
Critical areas of judgment:
Donations of consulting by Andrew Wakelin
Donations of conference guest speakers
(iii) Donations of services including printing. graphic design. meeting rooms and consultant attendance
of events
In accordance with the Charities SORP FRS 102, the charity has valued the benefit it receives from
donations in kind of £55.505 (2024.- £52,271). This is based on the open market value of benefits
received.
Income from donations and legacies
Restricted Unrestricted
funds
funds
2025
2025
Total
funds
2025
Total
funds
2024
Donations
6.478
6,478
21,556
5,000
134,550
52,271
4,018
Legacies
Grants
67,290
22.560
18.000
32,945
2,586
85,290
55,505
2,586
Donations in kind
Gift aid
Total 2025
89.850
60,009
149,859
217,395
Total 2024
155,150
62,245
217,395
Page 16

ASSOCIATION FOR GLYCOGEN STORAGE DISEASE (UK) LIMITED
(A company limited by guarantee)
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025
Income from charitable activities
Unrestricted
funds
2025
Total
funds
2025
Total
funds
2024
Subscriptions
830
830
875
Total 2024
875
875
Income from other trading activilies
Income from fundraising events
Restricted Unrestricted
funds
funds
2025
2025
Total
funds
2025
Total
funds
2024
Fundraising events
5.986
16.042
22,028
21,738
Total 2024
6,248
15,490
21,738
Investment income
Unrestrlcted
funds
2025
Total
funds
2025
Total
funds
2024
Investment income
1,235
1,235
1, 120
Total 2024
1, 120
1, 120
Page 17

ASSOCIATION FOR GLYCOGEN STORAGE DISEASE (UK) LIMITED
(A company limited by guarantee)
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025
Other incoming resources
Unrestricted
funds
2025
Total
funds
2025
Total
funds
2024
Other income
1,149
Total 2024
1, 149
1, 149
Analysis of grants
Grants to
Individuals
2025
Grants to
Institution
2025
Total
funds
2025
Total
funds
2024
Grants
1,900
24,616
26,516
12,728
Total 2024
420
12,308
12, 728
In 2025 1 grant was given to institutions {2024.- 1) and 8 to individuals (2024.. 1).
Page 18

ASSOCIATION FOR GLYCOGEN STORAGE DISEASE (UK) LIMITED
(A company limited by guarantee)
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025
10.
Analysis of expenditure by activities
Activities
undertaken
directly
2025
Grant
funding of
activities
2025
Support
costs
2025
Total
funds
2025
Total
funds
2024
Charitable activities
151,085
26.516
34,610
212,211
197,548
Total 2024
152,079
12,728
32,741
197,548
Analysis of direGI costs
Charitable
activities
2025
Total
funds
2025
Total
funds
2024
Staff costs
Conference expenses
Walking Course
Consultancy
Travel and accommodation expenses
Freelancer consulting costs
Patient and Family meetings
24,533
32,764
24,533
32,764
24,533
27,449
9,848
52,271
928
55,505
940
55,505
940
37,090
253
37,090
253
37,050
Total 2025
151.085
151,085
152,079
Total 2024
152,079
152,079
Page 19

ASSOCIATION FOR GLYCOGEN STORAGE DISEASE (UK) LIMITED
(A company limited by guarantee)
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025
10.
Analysis of expenditure by activities (continued)
Analysis of support costs
Charitable
activities
2025
Total
funds
2025
Total
funds
2024
Rent
1,896
651
1,896
651
1,842
308
Office Costs
Online services
Website and computer costs
Sundry expenses
Subscriptions
Insurance
1,095
8.446
10
1,095
8,446
10
962
10,594
425
566
566
599
677
677
706
3,189
101
216
Printing, post and stationery
Fundraising
Depreciation - office equipment
Amortisation - website development
Staff training
Accountancy & payroll
Independent examiners fee
Staff costs
4.064
320
204
4,064
320
204
11,438
3.186
2.057
11,438
3,186
2,057
9, 602
2,963
1,234
Total 2025
34,610
34,610
32,741
Total 2024
32,741
32,741
During the year ended 31 March 2025. the company incurred the following Governance costs:
£14,624 (2024 - £12,590) included in the table above.
11.
Independent examinerfs remuneration
The independent examiner's remuneration amounts to an independent examiner fee of £3,186 (2024-
£2, 963).
Page 20

ASSOCIATION FOR GLYCOGEN STORAGE DISEASE (UK) LIMITED
(A company limited by guarantee)
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025
12.
Staff costs
2025
2024
Wages and salaries
Social security costs
Pension costs
24,000
2,057
533
24,000
1,234
533
26,590
25,767
The average number of persons employed by the company during the year was as follows:
2025
No.
2024
No.
The key management personnel of the charity are the Trustees and Chief Executive. Total employee
benefits of key management personnel of the charity were £24,533 (2024.. £24,533).
No employee received remuneration amounting to more than £60.000 in either year.
13.
Trustees. remuneration and expenses
During the year. no Trustees received any remuneration or other benefits (2024 - £NIL).
During the year ended 31 March 2025, expenses totalling f362 were reimbursed or paid directly to 1
Trustee (2024 - £NIL to 1 Trustees) to cover expenses incurred relating to travel expense reimbursement
for the Hepatic Get Together and Team Meetings.
Page 21

ASSOCIATION FOR GLYCOGEN STORAGE DISEASE (UK) LIMITED
(A company limited by guarantee)
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025
14.
Intangible assets
Website
developmen
Cost
At 1 April 2024
23,938
At 31 March 2025
23,938
Amortisation
At 1 April 2024
23,938
At 31 March 2025
23,938
Net book value
At 31 March 2025
At 31 March 2024
Page 22

ASSOCIATION FOR GLYCOGEN STORAGE DISEASE (UK) LIMITED
(A company limited by guarantee)
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025
15.
Tangible fixed assets
Office
equipment
Cost or valuation
At 1 April 2024
7,538
At 31 March 2025
7,538
Depreciation
At 1 April 2024
Charge for the year
6,740
204
At 31 March 2025
6,944
Net book value
At 31 March 2025
594
At 31 March 2024
798
Page 23

ASSOCIATION FOR GLYCOGEN STORAGE DISEASE (UK) LIMITED
(A company limited by guarantee)
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025
16.
Debtors
2025
2024
Due within one year
Other debtors
Prepayments and accrued income
5,106
1,043
2,512
966
6,149
3,478
17. Creditors: Amounts falling due within one year
2025
2024
Trade creditors
2,970
592
1,184
5,427
Other taxation and social security
Other creditors
1,933
4,927
Accruals and deferred income
10,173
6, 860
Page 24

ASSOCIATION FOR GLYCOGEN STORAGE DISEASE (UK) LIMITED
(A company limited by guarantee)
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025
18.
Statement of funds
Statement of funds - current year
Balance at
31 March
2025
Balance at 1
April 2024
Transfers
inlout
Income Expenditure
Unrestricted funds
General Funds - all funds
43.596
78,116
{67,087)
(18,638)
35,987
Balance at
31 March
2025
Balance at 1
April 2024
Transfers
inlout
Income Expenditure
Restricted funds
Type 2 Pompe
Type 5 Mcardle
Type 3 Cori
Type 1 Van Gierke
Type 6 Hers Fund
Type O
Better treatments and service
access
3,941
4.855
375
695
(3,512)
{23,870)
1,124
9,757
28,772
{375)
(12,775)
{602)
{165)
12.775
602
165
15,633
21,183
28,683
{22,088)
{26,574)
{35,706)
{24,616)
(8,758)
6,455
5,384
6,799
Help with living well
Support across the community
PHD Project
Hepatic
224
61.542
36,926
6,029
870
13,917
84,486
95,836
(145,124)
18,638
53,836
Balance at
31 March
2025
Balance at 1
April 2024
Transfers
inlout
Income Expenditure
Total of funds
128.082
173,952
(212,211)
89,823
Page 25

ASSOCIATION FOR GLYCOGEN STORAGE DISEASE (UK) LIMITED
(A company limited by guarantee)
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025
18.
Statement of funds (continued)
Statement of funds - prior year
Balance al
31 March
2024
Balance at
1 Apnl 2023
Transfers
in/out
Income Expenditure
Unrestricted funds
General Funds - all funds
24,159
80,879
(61,069)
(373)
43,596
Restricted funds
Type 2 Pompe
Type 5 Mcardle
Type 3 Cori
Type 1 Van Gierke
Type 6 Hers Fund
Conferences
Type O
Better treatments and service
access
7.294
8,528
3,309
17,532
602
21,331
165
(3,353)
(32,331)
(2, 934)
(4, 757)
3,941
4,855
375
28. 658
12,775
602
1, 190
(22,631)
110
165
15,733
23,833
18,134
73,850
(15,996)
(23, 826)
(18,343)
(12,308)
263
Help with living well
Support across the community
PHD Project
433
224
61,542
59,194
161,398
(136,479)
3T3
84,486
Total of funds
83,353
242,277
(197,548)
128,082
Page 26

ASSOCIATION FOR GLYCOGEN STORAGE DISEASE (UK) LIMITED
(A company limited by guarantee)
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025
19.
Summary of funds
Summary of funds - current year
Balance at
31 March
2025
Balance at 1
April 2024
Transfers
inlout
Income Expenditure
General funds
43.596
84,486
78,116
95,836
(67,087)
(145,124)
(18,638)
18,638
35,987
53,836
Restricted funds
128,082
173,952
(212,211)
89,823
Summary of funds - prior year
Balance at
31 March
2024
Balance at
1 Apn"12023
Transfers
in/out
Income Expenditure
General funds
24.159
59,194
80,879
161,398
(61,069)
(136,479)
(373)
373
43,596
84,486
Restricted funds
83,353
242,277
(197,548)
128,082
Page 27

ASSOCIATION FOR GLYCOGEN STORAGE DISEASE (UK) LIMITED
(A company limited by guarantee)
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025
19.
Summary of funds (continued)
Restricted Funds
Type 2 Pompe's
Supporting GSD Type 2. Pompe.
Type 5 McArdles
Supporting GSD Type 5. McArdle.
Type 3 Cori
Supporting GSD Type 3. Cori.
Type 1 Von Gierke
Supporting GSD Type 1. Von Gierke.
Type 6 Hers Fund
Supporting GSD Type 6. Hers.
Hardship Fund
Supporting patients and families suffering hardship.
Conferences
Supporting AGSD-UK Annual conference.
Medical Advisory Board
Supporting meetings of AGSD-UK Medical Advisors.
Specialist Care Advisor
Supporting the provision of a Pompe patient support v￿rker.
Type O
Supporting GSD Type O.
Patient Education and Empowemient
Supporting patients and families by providing family days.
Better treatments and service access
Supporting activities to promote better treatments and Servi￿ access through
research engagement and V￿rk with professionals and partners.
Page 28

ASSOCIATION FOR GLYCOGEN STORAGE DISEASE (UK) LIMITED
(A company limited by guarantee)
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025
19.
Summary of funds (continued)
Help with living well
Supporting activities to enable people affected to live well with GSDS, including
information. educational programmes and therapeutic activities.
Support across the community
Supporting activities to ensure support is available across the GSD community.
PHD Projects
Grant contribution to PhD studentship 1
Eating, physical activity and mental health.
Grant contribution to PhD studentship 2
Investigating digital biomarkers to support safe physical activity-
Hepatic
Supporting people affected by hepatic GSDS
Transfers between funds
A transfer of £6,455 was made during the year from the general fund to the Better Treatments and
Service Access fund, of £5,384 to the Help With Living Well fund, £6,799 to the Support Across the
Community fund to cover the deficits at the year end.
Transfers of £375 from Type 3 Cori fund, £12,775 from the Type 1 Van Gierke fund, £602 from the Type
6 Hers fund and £165 from the Type O fund were made to the Hepatic fund. The hepatic funds have been
amalgamated to recognise that funds allocated to GSD1 were intended for use across hepatic GSDS.
20.
Analysis of net assets between funds
Analysis of net assets between funds - current year
Restricted Unrestricted
funds
funds
2025
2025
Total
funds
2025
Tangible fixed assets
Current assets
594
594
53,917
(81)
45,485
(10,092}
99,402
(10,173)
Creditors due within one year
Total
53,836
35,987
89,823
Page 29

ASSOCIATION FOR GLYCOGEN STORAGE DISEASE (UK) LIMITED
(A company limited by guarantee)
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025
20.
Analysis of net assets between funds (continued)
Analysis of net assets between funds - prior year
Restricted Unrestricted
funds
funds
2024
2024
Total
funds
2024
Tangible fixed assets
Current assets
798
798
86, 020
(1,534)
48, 124
(5,326)
134, 144
(6,860)
Creditors due within one year
Total
84,486
43,596
128,082
21.
Pension commitments
The Charity operates a defined contribution pension scheme. The assets of the scheme are held
separately from those of the Charity in independentiy administered funds. The pension cost shown in note
11 represents the contributions payable by the Charity to these funds. Included in other creditors is a
balance of £8112024 - £104) which relates to the pension fund.
22. Related party transactions
There were no related paty transactions in the year ended 31 March 2025.
Page 30